Related Experiment Video
Updated: Oct 2, 2026
Auricular Acupressure as an Adjuvant Treatment for Wheezing in Stable Chronic Obstructive Pulmonary Disease
Published on: May 10, 2024
Anticholinergic drugs for wheeze in children under the age of two years
M L Everard1, A Bara, M Kurian
1Department of Paediatrics, Sheffield Children's Hospital, Western Bank, Sheffield, UK, S10 2TH. m.l.everard@sheffield.ac.uk
Insights
Anti-cholinergic therapy for infant wheeze shows mixed results. While parents report benefits at home, evidence does not support its routine use due to inconsistent clinical outcomes.
Area of Science:
- Pediatrics
- Respiratory Medicine
- Clinical Pharmacology
Background:
- Infant wheeze is common, often triggered by viral infections, and its increasing incidence is noted.
- Treatment for wheezing infants is controversial, with variable use and debated efficacy of anti-cholinergic agents.
Purpose of the Study:
- To evaluate the effectiveness of anti-cholinergic therapy in treating wheezing infants.
- To compare anti-cholinergic treatments with placebo and beta2-agonists.
Main Methods:
- Systematic review of randomized controlled trials (RCTs) comparing anti-cholinergic therapy to placebo or beta2-agonists.
- Included infants under two years with wheeze, excluding those with acute bronchiolitis or chronic lung disease.
Main Results:
- Combination therapy with ipratropium bromide and beta2-agonist reduced the need for additional treatment but showed no difference in emergency department response.
- No significant difference in hospital stay was observed between ipratropium bromide and placebo or beta2-agonist alone.
- Combined ipratropium bromide and beta2-agonist improved clinical scores at 24 hours compared to placebo; parents preferred ipratropium bromide for home use.
Conclusions:
- Insufficient evidence exists to universally recommend anti-cholinergic therapy for wheezing infants.
- While parents perceive benefits for home use, the overall clinical evidence does not support uncritical application.
Background:
Wheeze in infancy and early childhood is common and appears to be increasing though the magnitude of any increase is unclear. Most wheezing episodes in infancy are precipitated by respiratory viral infections. Treatment of very young children with wheeze remains controversial. Anti-cholinergics are often prescribed but practice varies widely and the efficacy of this form of therapy remains the subject for debate.
Objectives:
Wheeze in infancy and early childhood is common and appears to be increasing. Most wheezing episodes in infancy are a result of viral infection. Bronchodilator medications such as beta2-agonists and anti-cholinergic agents are often used to relieve symptoms, but patterns of use vary. The objective of this review was to assess the effects of anti-cholinergic therapy in the treatment of wheezing infants.
Search Strategy:
We searched the Cochrane Airways Group trials register and the reference lists of articles. We contacted researchers in the field and industry sources.
Selection Criteria:
Randomised trials that compared anti-cholinergic therapy with placebo or beta2-agonists in wheezing children under two years of age. Children with acute bronchiolitis and chronic lung disease were excluded.
Data Collection And Analysis:
Eligibility for inclusion and quality of trials were assessed independently by two reviewers.
Main Results:
Six trials involving 321 infants in three different settings were included. Compared with beta2-agonist alone, the combination of ipratropium bromide and beta2-agonist was associated with a reduced need for additional treatment, but no difference was seen in treatment response, respiratory rate or oxygen saturation improvement in the emergency department. There was no significant difference in length of hospital stay between ipratropium bromide and placebo; or between ipratropium bromide and beta2-agonist combined compared with beta2-agonist alone. However, combined ipratropium bromide and beta2-agonist compared to placebo showed significantly improved clinical scores at 24 hours. Parents preferred ipratropium bromide over nebulised water or placebo for relief of their children's symptoms at home.
Reviewer'S Conclusions:
There is not enough evidence to support the uncritical use of anti-cholinergic therapy for wheezing infants, although parents using it at home were able to identify benefits.
Related Concept Videos
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
01:26Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
01:15Upper Respiratory Drugs: First and Second-Generation Antihistamines
Histamine binds to specific receptor sites, known as H1 receptors, on tissue cells, triggering inflammation and swelling. Antihistamines combat these effects by competing with histamine for these receptor sites. By...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses